Monte Rosa Therapeutics Financials - Benzinga

Monte Rosa Therapeutics Inc

GLUENASDAQ

Trade with Public

Trade with Public

$15.88

0.171.08%

At close: Aug 6, 5:00 PM EST

$15.88

0.171.08%

Pre-Market: 4:08 AM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Monte Rosa Therapeutics Financials

Monte Rosa Therapeutics (GLUE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over earnings of $0.57 per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over earnings of $0.23 per

Benzinga Newsdesk

Crude Oil Down 2%; ISM Services PMI Surges In December

Avi Kapoor

PRO
Monte Rosa Therapeutics Q3 EPS $(0.33) Beats $(0.37) Estimate, Sales $12.768M Beat $5.420M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.37) by 11.53 percent. This is a 13.79 percent decrease over losses of $(0.29) per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216

Benzinga Newsdesk